Instead of merely focusing on publicly available financials, a serious investor with a long-term view should also focus equally on the intangibles like how diligently the company stuck to its original business plan & grew, whether its fund raising milestones resulted in capacity buildup, expansion et al - At every time-point wherein Laurus Labs attracted new funds, the revenue showed a significant jump in the subsequent year, The more interesting thing is how Laurus worked towards achieving goals set forth at the time of incorporation (2005);
From what can be mapped out from publicly available resources, Laurus business plan of early days included focusing on the following aspects;
- Being a 2000 Cr company by 2016 -- it will be in 2017
- Building capabilities strategically across two different asset types; 1) High volume, low value APIs & 2) High Value low volume APIs -accordingly they developed a strong portfolio of ARV (anti-AIDS) & Oncology (cancer) APIs
- Being among the the ''Top 3'' in whichever segment we deal in - accordingly Laurus today commands a leadership position in sheer supply of most first line regimen ARV APIs (>50% of world consumption of API) & some Oncology; HCV APIs
- The future business strategy always included forward integration for adding value to the client offering - but utilizing the core competence as the base (API) - accordingly, Laurus is aggressively pursuing FDF business forward integrating the APIs that it already has a leadership position in.
Its a rarity companies stick to the original growth plans without taking a pivot at every two years, given Laurus''s excellent track record in this, there is no doubt that it will soon breach the USD 1 billion revenue mark in the next five years.
Finally comparing it with peers like Divis & Aurobindo is not completely right. Divis model is prominently based on CRAMS while Laurus business is based on its own R&D stregth/ IP. While Aurobindo business template may be similar to Laurus, it should not be forgotten that Laurus achieved a lot more in its 10 years of existence.
I already bet my money on Laurus Labs, I suggest you do too!
Listing gains are unpredictable for this issue ...
I am applying ... with a target of Rs.470+ after 4 weeks of listing
I am applying for 13 lots in each application ... because I believe that the RII quota may not be fully subscribed. Ap ka ye message kya kah raha he. Ki 470 ke uppar 4 week ke bad jayega